Gabriel Hinojosa, PharmD, BCOP, explores unmet needs and social determinants in multiple myeloma care, envisioning treatment advancements amid evolving complexities and patient disparities.
Gabriel Hinojosa, PharmD, BCOP, looks beyond frontline regimens in multiple myeloma, and discusses treatment options, adverse events, and complexities in sequencing therapies.
Gabriel Hinojosa, PharmD, BCOP, provides insights on selecting the best treatment regimen, and considers comorbidities, adverse events, and therapy modifications in multiple myeloma treatment.
Gabriel Hinojosa, PharmD, BCOP, reviews head-to-head comparisons in multiple myeloma regimens and evaluates efficacy and safety implications in treatment selection.
Gabriel Hinojosa, PharmD, BCOP, analyzes eligibility factors and treatment shifts in multiple myeloma care, considering autologous stem cell transplant risks and evolving therapy approaches with daratumumab.